Patent ID: 7939497

Claim:
A method for treating cancer associated with Slit2 mediated tumor angiogenesis in a subject, which method comprises: administering a compound effective to reduce or prevent Slit2-Slit2 receptor protein-protein interaction to the subject at a level sufficient to treat the cancer associated with Slit2 mediated tumor angiogenesis in said subject, wherein the cancer is a solid tumor cancer that comprises cells expressing Slit2, and wherein the solid tumor cancer is adenoid cystic carcinoma of salivary gland or hepatocellular carcinoma; and wherein the compound that reduces or prevents Slit2-Slit2 receptor protein-protein interaction is selected from the group consisting of an anti-Slit2 antibody, an anti-Slit2 receptor antibody and a Slit2 receptor fragment derived from extracellular domain of the Slit2 receptor that is capable of binding to Slit2.